Assertion Supported
Wickramasekara: Major pharma increasingly licenses drug molecules from China
“We've seen this huge uptick in pharma going to China and buying molecules that they typically would have bought from American biotechs.”
Insight
Wickramasekara: Clinical trial optimization is a red herring versus molecule quality
“People get very focused on clinical trials because they're like the biggest line item. And they're important, don't get me wrong, but I think it's actually a bit of a red, red herring. Where, ah, yes, there are operational problems. Like, some studies are desi…”
Prediction Held up
Wickramasekara: GLP-1s will probably be the best-selling drugs of all time
“And then all of a sudden, like we have this category defining medicine that's going to go on to probably be the best selling drug of all, all time.”
Prediction Not checkable as stated
Wickramasekara: AI in scientific discovery will focus on augmentation over autonomy next 1-2 years
“While I would love for that to happen, and I'm maybe more optimistic on a longer time scale, we will get there. I think in the short term, I'm next one to two years, which, you know, already feels like an eternity in AI time. I'm a little bit more bullish on s…”
Assertion Not checkable as stated
Wickramasekara: Most Biotech Researchers Are Not Yet Using Much AI in R&D
“Most people aren't really using that much AI and R&D yet. They all want to, they're primed to, but there's a lot of concerns about accuracy, IP, security, legal. And I think the farther you go from SF, the like, Larger those concerns, concerns get.”
Prediction Not checkable as stated
Wickramasekara: Pure AI biology model companies must morph into biopharma
“I think it's unlikely, it's possible, but it's unlikely that sort of, hey, they're just gonna remain pure model companies who just do deals with pharma, where pharma, you know, pays them a hundred million dollars upfront or something like that, and they have f…”
Insight
Wickramasekara: 5 to 10 customers represent what an entire vertical industry needs
“I find that having five, 10 customers is actually like a pretty representative model for what the entire industry needs.”
Opinion
Wickramasekara: Recent years in biotech equal a dot-com level bust
“We're probably like the last couple of years are probably like the equivalent of like the dot com bust happening for biotech.”
Opinion
Wickramasekara: Novel biotech modalities are in a trough of disillusionment
“I think investors and companies got very excited and put a lot of money into these categories, and we're kind of in the trough of disillusionment for some of them now.”
Prediction Not checkable as stated
Wickramasekara: Next decade of biotech will focus on speed and cost
“If the last decade was about sort of biologics and these new modalities, I think the next is going to be about speed and cost.”
Assertion Supported
Wickramasekara: Prescription drugs account for 9% of US healthcare spending
“I think nine percent of healthcare spent, prescription drug sales are nine percent of healthcare spending in the U.S.”
Assertion Not checkable as stated
Wickramasekara: Obesity drugs were completely unfundable five years ago
“So GLP-Ins obviously have just transformed obesity as, like, a treatable disease when, by the way, it was, like, a totally unfundable category of things, like, five years ago.”
Insight
Wickramasekara: Much of scientific research is lost to institutional folklore
“And so there's so much of science that lives in like folklore and institutional knowledge, and that's kind of lost over time.”
Insight
Wickramasekara: High-stakes AI requires human accountability to bear legal liability
“And truthfully, like at the end of the day, you probably like, you know, with a radiologist, you probably need a human to be accountable For those decisions, it's not just about the technology. Like, someone, someone's gotta be there to, like get sued if somet…”
Opinion
Wickramasekara: Biology AI has powerful models but lacks a ChatGPT-like interface
“I think we're like, we've got GPT, but there's no chat. Like, that, that's kind of how I think about it. Like, I think the chat, and I mean chat metaphorically, like, that was the interface that made things really take off in, in software. And I don't think it…”
Insight
Wickramasekara: 90% of vertical AI is workflow translation and building trust
“I think in a vertical, I think 90% of the work is actually, like, translation. It's taking something and making science, making sure scientists trust it, it's the right point in their workflow, it's easy to use, and it's accurate.”
Assertion Not checkable as stated
Wickramasekara: Large pharma is piloting AI without organizational transformation yet
“Most of the
Large pharma at this point that I've worked with, like, you know, they've got co-pilot and things like that, and they're doing a lot of pilots of different technologies, but I haven't seen their orgs transformed yet.”
Assertion Not checkable as stated
Wickramasekara: Large pharma generates model-training data at scale startups cannot match
“They can generate data to train their own models at a scale that most biotech startups can't match.”
Prediction Not checkable as stated
Wickramasekara: Large pharma will produce unique proprietary predictive models
“I think while it's early on sort of the agentic how we work side, I think you're going to see very unique models come out of pharma where their computational scientists are building interesting predictive models that, you know, similar to what's happening in t…”
Insight
Wickramasekara: AI drug development requires optimizing every pipeline step, not one-shot generation
“My mental model is like, there are so many steps. Those steps are all cumbersome and difficult. And this is a game of like making each single thing better. And, like, some of the steps matter more than others, like, having the right target or having, like, a g…”
Insight
Wickramasekara: Biopharma rarely buys early data due to lack of trust
“You see very, very few transactions of data. That's because no one trusts anyone else's data. You wait till there's a clinical trial, and the data is positive, and you buy the molecule. But you'd think that you'd see a lot more selling of data before that. But…”
Prediction Not checkable as stated
Wickramasekara: AI will convert life sciences skeptics to structured data tools
“But now with like AI, one, I think the benefits are a much more immediately obvious to everyone. And so that's going to be this amazing tailwind to try to like do better here. And I think it will convince a lot of people who might have been skeptics in the pas…”
Insight
Wickramasekara: Science is uniquely structured to benefit from LLM architectures
“I go back to that sort of returns to intelligence piece where I think science is a problem that has some shape to it that really benefits from the LLM architecture. Like you just think about the corpus of scientific literature as like this vast pool of unstruc…”
Insight
Wickramasekara: A co-founder's true power lies in moral authority
“I feel like the power of being a co-founder is actually just in moral authority”
